Although the biggest contribution to the therapeutic effect of amivantamab is likely due to EGFR inhibition, it is reasonable to speculate that synergistic targeting of MET must be a factor to help offer better tumor selectivity and avoid major toxicity resulting from WT EGFR inhibition. This evidence concerns the gene EGFR and neoplasm.